Early Asset Strategy

In today’s healthcare environment, there is a strong need to create and deliver value for all relevant stakeholders right from the start. A thought-through early asset strategy increases the chance of commercial success by including stakeholder insights ahead of time, with the right level of investment driving key decisions early on and throughout the entire lifecycle. 

Focusing primarily on regulatory success is no guarantee for commercial success with adequate patient access and uptake. And many gaps that lead to commercial failure can be identified and addressed with an early value proposition, early in an asset’s lifecycle.

It’s about taking different perspectives and creating a value proposition that resonates with all stakeholders’ needs – while taking into consideration the evolving competitive landscape as well. Companies that are able to integrate all different needs early on into a coherent cross-functionally aligned strategy, demonstrate how to succeed in today’s healthcare systems. 

In our methodology perspectives of all relevant stakeholder groups drive the asset’s value proposition:

• Patients: Why use it?
• Policy makers: Why fund it?
• Regulators: Why approve it?
• Providers and HCPs: Why prescribe it?
• Payers: Why pay for it?
• Competitors: What differentiates it?

These perspectives get translated and cross-functionally aligned into a tangible set of parameters that can be tested to evaluate the strength of the value proposition and to inform the asset strategy. The rating provides an easy assessment of the opportunities and risks in the commercialization strategy of the asset, highlighting gaps and priority investments.